Faaborg, L.; Andersen, R.F.; Waldstrøm, M.; Henriksen, J.R.; Adimi, P.; Jakobsen, A.; Steffensen, K.D.
Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. Cancers 2022, 14, 1766.
https://doi.org/10.3390/cancers14071766
AMA Style
Faaborg L, Andersen RF, Waldstrøm M, Henriksen JR, Adimi P, Jakobsen A, Steffensen KD.
Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. Cancers. 2022; 14(7):1766.
https://doi.org/10.3390/cancers14071766
Chicago/Turabian Style
Faaborg, Louise, Rikke Fredslund Andersen, Marianne Waldstrøm, Jon Røikjær Henriksen, Parvin Adimi, Anders Jakobsen, and Karina Dahl Steffensen.
2022. "Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer" Cancers 14, no. 7: 1766.
https://doi.org/10.3390/cancers14071766
APA Style
Faaborg, L., Andersen, R. F., Waldstrøm, M., Henriksen, J. R., Adimi, P., Jakobsen, A., & Steffensen, K. D.
(2022). Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. Cancers, 14(7), 1766.
https://doi.org/10.3390/cancers14071766